Evidence map›Paper›PMID 33986614›Full record

ArticleCancer management and research2021

The Predominant Prognostic Significance of

Katarzyna Skórka, Michał Chojnacki, Marta Masternak, Agnieszka Karczmarczyk, Edyta Subocz, Ewa Wawrzyniak, Krzysztof Giannopoulos

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Katarzyna SkórkaDepartment of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland.
Michał ChojnackiDepartment of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland.ORCID 0000-0002-7296-2802
Marta MasternakDepartment of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland.ORCID 0000-0001-5947-7610
Agnieszka KarczmarczykDepartment of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland.
Edyta SuboczDepartment of Internal Medicine and Hematology, Military Institute of Medicine, Warsaw, Poland.
Ewa WawrzyniakDepartment of Hematology, Medical University of Lodz, Lodz, Poland.
Krzysztof GiannopoulosDepartment of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland.
Medical University of Lublin · PLMedical University of Lodz · PLWojskowy Instytut Medycyny Lotniczej · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePATIENTS AND

methodsThis study included 319 untreated CLL patients. Two PCR-based methods; ddPCR and ARMS-PCR were performed to assess the mutational status of

resultsWe proved that ddPCR increased the detectability of the

conclusionThe selection of the precise method of

Indexed as

amplification-refractory mutation system PCRARMS-PCRchronic lymphocytic leukemiaCLLddPCRdroplet digital PCRNOTCH1prognostic marker

Identifiers

PMID33986614
PMCPMC8110254
OpenAlexW3157088043

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.